Royalty Pharma plc (OQ:RPRX)

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEC
Company Contact
Address: 110 East 59th Street
Tel: N/A
IR: See website
Key People
Pablo Legorreta
Chairman of the Board, Chief Executive Officer
Christopher D. Hite
Vice Chairman, Executive Vice President
Terrance Coyne
Chief Financial Officer, Executive Vice President
George Lloyd
Executive Vice President - Investments and Chief Legal Officer
Marshall Urist
Executive Vice President - Research and Investments
Eric Schneider
Senior Vice President, Chief Technology Officer
Business Overview
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on more than 35 commercial products, including Vertexs Trikafta, Kalydeco, Orkambi and Symdeko, Biogens Tysabri, AbbVie and Johnson & Johnsons Imbruvica, Astellas and Pfizer's Xtandi, GSKs Trelegy, Novartis Promacta, Pfizer's Nurtec ODT, Johnson & Johnsons Tremfya, Roches Evrysdi, Gilead's Trodelvy, and 12 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Olpasiran, Omecamtiv mecarbil, Pelabresib, Pelacarsen, Seltorexant, Trontinemab, Tulmimetostat and Zavegepant. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.
Financial Overview
For the fiscal year ended 31 December 2023, Royalty Pharma plc revenues increased 5% to $2.35B. Net income increased from $42.8M to $1.13B. Revenues reflect Other royalty income increase from $74.6M to $156M, Income from financial royalty assets increase of 3% to $2.2B. Net income benefited from Financial royalty asset impairment decrease from $615.8M (expense) to $0K.
Employees: 89 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $22,783M as of Dec 31, 2023
Annual revenue (TTM): $2,355M as of Dec 31, 2023
EBITDA (TTM): $1,492M as of Dec 31, 2023
Net annual income (TTM): $1,135M as of Dec 31, 2023
Free cash flow (TTM): $513.95M as of Dec 31, 2023
Net Debt Last Fiscal Year: $4,902M as of Dec 31, 2023
Shares outstanding: 597,484,791 as of Feb 9, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.